Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with binimetinib in treating patients with solid tumors that carry RAS alterations and that have spread to other places in the body (advanced/metastatic) or cannot be removed by surgery (unresectable). ZEN003694 is an oral medication with potential anticancer activity. It is an inhibitor of a family of proteins called bromodomain and extra-terminal (BET) which play important role during development and cellular growth. ZEN003694 may stop the growth of tumor cells that produce BET. Binimetinib is in a class of medications called kinase inhibitors. It works by blocking the action proteins called MEK1 and MEK2, that signal cancer cells to multiply. It may help keep cancer cells from growing and spreading. There is pre-clinical evidence that using ZEN003694 and binimetinib together may shrink or stabilize cancers studied in this trial. There are two parts of this study; dose escalation and dose expansion. In the dose escalation part of this study, different people will get different doses of the study drugs ZEN003694 and binimetinib. In the dose expansion part of this study, the highest dose with manageable side effects will be given to additional people. This will help to understand the side effects that may happen with this drug combination.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie zaawansowany lub rozprzestrzeniający się nowotwór stały, który nie reaguje na standardowe leczenie lub powrócił po leczeniu
- •Rak piersi potrójnie ujemny (TNBC) lub nowotwór z mutacją genów KRAS, NRAS, HRAS, BRAF lub innymi zmianami genetycznymi RAS
- •Zmiana genetyczna potwierdzona badaniem genetycznym (NGS)
- •Wiek co najmniej 18 lat
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu (ECOG 0-2)
- •Wystarczająca liczba komórek krwi i prawidłowe funkcje wątroby i nerek
- •Przerwa co najmniej 4 tygodnie od poprzedniego leczenia chemioterapią lub innymi lekami przeciwnowotworowych
- •Przerwa co najmniej 4 tygodnie od ostatniej radioterapii
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (4)
Boston Medical Center
Boston, United States
Dana-Farber Cancer Institute
Boston, United States
University of Texas Medical Branch
Galveston, United States
UT MD Anderson Cancer Center
Houston, United States
Trial contact
Site Public Contact
Avi B. Markowitz
PRINCIPAL_INVESTIGATOR
Site Public Contact
Sarina A. Piha-Paul
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.